HCM
IPXL

Highbridge Capital Management’s Impax Laboratories, Inc. IPXL Stock Holding History

Highbridge Capital Management’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-123,705
Closed -$5.68M – 1967
2015
Q2 		$5.68M Buy
+123,705
New +$5.87M 0.07% 283
2013
Q4 		– Sell
-210,612
Closed -$4.31M – 1459
2013
Q3 		$4.31M Buy
+210,612
New +$4.35M 0.05% 359

Other funds holding IPXL

HP
Hound Partners New York $799M AUM 9.54% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Aravt Global New York $11.3M AUM 3.78% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
PCM
Pennant Capital Management Summit, New Jersey $212M AUM 19.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Highbridge Capital Management's IPXL Position: Q3 2015 in Review

Highbridge Capital Management sold out of Impax Laboratories, Inc. (IPXL) in Q3 2015, closing a stake of 123,705 shares — an estimated $5.68M sold.

Highbridge Capital Management first reported a position in IPXL in Q3 2013 and held it in 2 quarters. The position peaked at $5.68M in Q2 2015. 195 funds tracked by Wall St. Rank hold IPXL as of Q3 2015.

  • Highbridge Capital Management reported no remaining Impax Laboratories, Inc. position as of Q3 2015 after selling out during the quarter.
  • Highbridge Capital Management sold 123,705 Impax Laboratories, Inc. shares in Q3 2015, an estimated $5.68M.
  • Highbridge Capital Management first reported a position in Impax Laboratories, Inc. in Q3 2013 and held it in 2 quarters.
  • Highbridge Capital Management's Impax Laboratories, Inc. position peaked at $5.68M in Q2 2015.
  • 195 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q3 2015.

Based on Highbridge Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.